|
 The company, known for its aspirin and Yasmin birth control pills,
said it asked authorities in the U.S., Japan and Europe to extend
the marketing authorization of the drug, which is already approved
for the treatment of colorectal cancer and gastrointestinal stromal
tumors.
Bayer added that Regorafenib was accepted for an expedited approval
process in the United States, known as a Fast Track designation.
The drugmaker in May said that a Phase III clinical trial of
Regorafenib showed it helped extend the lives of liver cancer
sufferers -- a disease around 780,000 people worldwide are diagnosed
with each year.
(Reporting by Tina Bellon, editing by Louise Heavens)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
